More on ImClone's mystery bidder

The identity of ImClone's mystery bidder will be revealed tomorrow even if it does not make a final offer, the company said, as the Financial Times reported that the bidder was a U.S.-based drugmaker with "pipeline synergies" with its buyout target. Report | Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.